Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

JNJ-40346527

Known as: FMS Inhibitor JNJ-40346527 
A small molecule and orally available inhibitor of colony-stimulating factor-1 receptor (CSF1R; FMS) with potential antineoplastic activity. FMS… Expand
National Institutes of Health

Related topics

Related topics

5 relations

Broader (2)

ImidazolesPyridines
Inhibition of Cell ProliferationReceptor Tyrosine Kinase InhibitionSignal Transduction Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
CSF1R inhibitor JNJ-40346527 attenuates microglial proliferation and neurodegeneration in P301S mice
Microglia have been implicated in amyloid beta-induced neuropathology, but their role in tau-induced neurodegeneration remains… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2019
2019
The CSF-1-receptor inhibitor, JNJ-40346527 (PRV-6527), reduced inflammatory macrophage recruitment to the intestinal mucosa and suppressed murine T cell mediated colitis
Background & aims Originally believed to be primarily a disorder of T-cell signaling, evidence shows that macrophage-lineage… Expand
  • figure 1
  • figure 2
  • figure 4
  • figure 5
  • figure 6
Review
2018
Review
2018
Recent advances in colony stimulating factor-1 receptor/c-FMS as an emerging target for various therapeutic implications.
Colony stimulating factor-1 (CSF-1) is one of the most common proinflammatory cytokine responsible for various inflammatory… Expand
2016
2016
Inhibition of the colony-stimulating-factor-1 receptor affects the resistance of lung cancer cells to cisplatin
In the present work we show that multiple lung cancer cell lines contain cisplatin resistant cell subpopulations expressing the… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
2015
2015
An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma
Purpose: This phase I/II study investigated JNJ-40346527, a selective inhibitor of the colony-stimulating factor-1 receptor (CSF… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
2015
2015
Results from a Phase IIA Parallel Group Study of JNJ-40346527, an Oral CSF-1R Inhibitor, in Patients with Active Rheumatoid Arthritis despite Disease-modifying Antirheumatic Drug Therapy
Objective. To assess the efficacy and safety of JNJ-40346527, a selective inhibitor of colony-stimulating factor-1 (CSF-1… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
2014
2014
THU0133 Results from A Phase 2A, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Study of Jnj-40346527, an Oral CSF-1R Inhibitor, in Patients with Active Rheumatoid…
Background JNJ-40346527, an investigational agent, is a selective inhibitor of the colony stimulating factor-1 receptor (CSF-1R… Expand
Review
2013
Review
2013
A Phase 1 Study Of JNJ-40346527, a Colony Stimulating Factor-1 Receptor (CSF-1R) Inhibitor, In Patients With Relapsed Or Refractory Hodgkin Lymphoma
Introduction JNJ-40346527 is a selective inhibitor of the colony stimulating factor-1 receptor (CSF-1R) tyrosine kinase. It… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE